We transcend the medication to approach the different pathologies in a holistic way, always focusing on the patient
Business
DISEASES
We want to approach the treatment of certain disabling pathologies in many aspects of daily life with a holistic view that involves putting the disease at the centre to alleviate the negative effects of its social dimension and make living with the disease more bearable.
-
Huntington's disease
Es una enfermedad neurodegenerativa rara y hereditaria que provoca una muerte neuronal progresiva y se manifiesta como un deterioro de las funciones cognitivas, conductuales y motoras. -
Amyotrophic lateral sclerosis
Patología neurodegenerativa que debilita los músculos. -
Progressive supranuclear palsy
Trastorno cerebral que afecta el equilibrio, la vista y el movimiento. -
Pulmonary hypertension
Enfermedad producida por presión elevada en los vasos sanguíneos de los pulmones. -
Pulmonary arterial hypertension
Patología específica de hipertensión pulmonar que afecta directamente a las arterias pulmonares. -
Pulmonary hypertension associated with interstitial lung disease
Alta presión en vasos pulmonares asociada a enfermedades intersticiales. -
Progressive pulmonary fibrosis
Enfermedad pulmonar con empeoramiento continuo de la función respiratoria. -
Idiopathic pulmonary fibrosis
Cicatrización progresiva del pulmón sin causa conocida.
Understanding to transform
We look beyond the drug because we know that behind every diagnosis there is a person, and that the experience of the disease is not defined only by its clinical aspects, but by a broader environment of relationships, systems and interactions. For this reason, we take a comprehensive view that leads us to understand the ecosystem that surrounds each disease, working together with patients, caregivers, healthcare professionals, researchers, regulators and associations.
This knowledge allows us to move towards more relevant solutions with a greater real impact, which transcend the treatment itself and address aspects such as awareness, diagnosis, access or accompaniment. We understand that the impact of the disease goes beyond the person, also affecting those around them, and that progress is only possible through collaboration. Therefore, we promote dialogue and shared learning to help generate lasting value for all those affected.
Related news
-
Ferrer and Prilenia Announce Start of PRECISE-HD Confirmatory Clinical Trial of Pridopidine in Huntington's Disease
5 -
First participant in Europe in the Phase 3 clinical trial "PREVAiLS" with pridopidine, in ALS
5 -
IMPAHCT celebrates its eighth edition by reinforcing the comprehensive approach to rare lung diseases
5 -
Ferrer and Prilenia Announce Inclusion of First Participant in Phase 3 Clinical Trial "PREVAiLS" with Pridopidine, in ALS
5
